Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Spira

Showing results (51-60 of 83) with videos related to

Pageof 9
Sort By:
Lancet (London, England)|March 14, 2016
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLouis Fehrenbacher, Alexander Spira, Marcus Ballinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2019
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid TumorsRastislav Bahleda, Antoine Italiano, Cinta Hierro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2025
Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor Positive, HER2 Negative Advanced Breast CancerRobert Wesolowski, Hope S Rugo, Jennifer M Specht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2023
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01Toshio Shimizu, Jacob Sands, Kiyotaka Yoh, et al.
The Lancet. Haematology|May 28, 2021
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion studyMehdi Hamadani, Graham P Collins, Paolo F Caimi, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2023
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS studyKeunchil Park, Joshua K Sabari, Eric B Haura, et al.
JCO Oncology Practice|October 25, 2021
Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO RegistryKathryn F Mileham, Suanna S Bruinooge, Charu Aggarwal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2015
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global StudySai-Hong Ignatius Ou, Jin Seok Ahn, Luigi De Petris, et al.
Clinical and Translational Science|August 10, 2020
Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181)John Powderly, Alexander Spira, Shunsuke Kondo, et al.
Cancer|December 17, 2013
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancerWalter M Stadler, David J Vaughn, Guru Sonpavde, et al.
Pageof 9

Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
Lancet (London, England)|March 14, 2016
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLouis Fehrenbacher, Alexander Spira, Marcus Ballinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2019
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid TumorsRastislav Bahleda, Antoine Italiano, Cinta Hierro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2025
Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor Positive, HER2 Negative Advanced Breast CancerRobert Wesolowski, Hope S Rugo, Jennifer M Specht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2023
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01Toshio Shimizu, Jacob Sands, Kiyotaka Yoh, et al.
The Lancet. Haematology|May 28, 2021
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion studyMehdi Hamadani, Graham P Collins, Paolo F Caimi, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2023
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS studyKeunchil Park, Joshua K Sabari, Eric B Haura, et al.
JCO Oncology Practice|October 25, 2021
Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO RegistryKathryn F Mileham, Suanna S Bruinooge, Charu Aggarwal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2015
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global StudySai-Hong Ignatius Ou, Jin Seok Ahn, Luigi De Petris, et al.
Clinical and Translational Science|August 10, 2020
Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181)John Powderly, Alexander Spira, Shunsuke Kondo, et al.
Cancer|December 17, 2013
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancerWalter M Stadler, David J Vaughn, Guru Sonpavde, et al.
Pageof 9